(1) MAP kinases |
Human breast cancer cell MCF-11 |
47 |
(2) Fas redistribution in the rafts |
Colon cancer cells |
48 |
(3) Ceramide |
Breast cancer cells |
49 |
(4) STAT3 and nuclear factor-κB-regulation |
Human multiple myceloma cells |
50 |
(5) Protein kinases and p38 kinase |
Antitumor activity |
51 |
(6) Src and Stat3 |
Breast cancer |
52 |
(7) TRAIL-induced |
Mitochondria |
53 |
(8) Phosphorylated Akt and Caspace-9 |
MCF7 human breast cancer cells |
54 |
(9) Cdc42 activation of ASK1/JNK |
Human leukemia cancer cells |
55 |
(10) Phosphatidylinositol 3′-kinase Akt |
Human prostate cancer cells |
56 |
(11) WAF-1/p21-mediated G1 phase |
Human epidermoid Carcinoma A431 cells |
57 |
(12) AMPK |
Colon cancer cells |
58 |
(13) JNK and c-JUN/AP-1 |
Prevented HNE-induced JNK |
59 |
(14) c-Myc |
Downregulation in human medulloblastoma |
60 |
(15) ERK |
Initiates p53 dependent apoptosis via αVβ3 |
61 |
(16) Caspase-3 |
Human breast cancer cell |
62 |
(17) CD95 |
Human tumor cells |
63 |
(18) TNBS |
Inhibiting Notch pathway |
64 |
(19) p53 and P13K/Akt |
Human T-cell acute lymphoblastic leukemia MOLT-4 cells |
65 |